clinical trial · NCT00783146
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)
Organon and Co·phase4·completed·n = 728
Seasonal Allergic Rhinitisdesloratadinefexofenadineplacebo
brief summary
This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.
started
Aug 1, 2004
primary completion
Oct 1, 2004
completion
Oct 1, 2004
last updated
Aug 15, 2024
official title
A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol